Expression of VEGF, EGF and HGF in early‑ and late‑stage colorectal cancer

Abdulla,Maha-Hamadien; Shaik,Asma Sultana; Vaali‑Mohammed,Mansoor-Ali; Al Khayal,Khayal Abdulmalik; Traiki,Thamer Bin; Zubaidi,Ahmad Mohammed; Al‑Johani,Tariq; Shakoor,Zahid; Al-Obeed,Omar Abdullah

doi:10.3892/mco.2021.2413

Expression of VEGF, EGF and HGF in early‑ and late‑stage colorectal cancer

Authors:
- Maha-Hamadien Abdulla
- Asma Sultana Shaik
- Mansoor-Ali Vaali‑Mohammed
- Khayal Abdulmalik Al Khayal
- Thamer Bin Traiki
- Ahmad Mohammed Zubaidi
- Tariq Al‑Johani
- Zahid Shakoor
- Omar Abdullah Al-Obeed
View Affiliations

Affiliations: Colorectal Research Chair, Department of Surgery, King Khalid University Hospital, College of Medicine, King Saud University, Riyadh 11472, Saudi Arabia, Prince Naif Health Research Centre, King Saud University, Riyadh 11472, Saudi Arabia, Department of Pathology and Laboratory Medicine, College of Medicine, King Saud University Medical City, Riyadh 11472, Saudi Arabia, Department of Immunology, King Saud University Medical City, Riyadh 11472, Saudi Arabia
Published online on: October 8, 2021 https://doi.org/10.3892/mco.2021.2413
Article Number: 251

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The heterogenous nature of colorectal cancer (CRC) highlights the need for a better understanding of the growth factors that affect tumour growth and cancer progression. The aim of the present study was to evaluate the role of epidermal growth factor (EGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in the early (I and II) and late (III and IV) stages of CRC. The serum levels and mRNA expression (n=30) of the aforementioned growth factors were measured and immunohistochemistry (n=20) was performed in patients with CRC. Histological examination revealed comparable distribution of early‑stage [I: 8 (26.7%) and II: 7 (23.3%)] and late‑stage [III: 8 (26.7%) and IV: 7 (23.3%)] CRC. The mean serum concentrations of VEGF during the early (152.9±14.5 vs. 88.39±3.99 pg/ml; P=0.001) and late (182.7±25.8 vs. 88.39±3.99 pg/ml; P=0.002) stages were significantly higher compared with those in controls. Similarly, the mean serum concentrations of EGF in the early (409.4±7.96 vs. 153.7±13.8 pg/ml; P=0.05) and HGF in the late (90.4±17.4 vs. 56.9±4.97 pg/ml; P=0.05) stages were significantly higher compared with those in controls. The serum concentrations of VEGF, EGF and HGF were comparable between the early and late stages of CRC. Compared to normal tissues, the mRNA expression of both VEGF (P<0.001) and HGF (P<0.01) was upregulated in early‑stage and downregulated in late‑stage CRC. The expression of EGF remained significantly elevated during both the early and late stages of CRC (P<0.01). Histopathological analyses confirmed increased expression of VEGF in cancerous tissues compared with that in normal tissues. The present study emphasized the need for monitoring the serum levels and tissue expression of growth factors to fully elucidate their role in patients with CRC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2020. CA Cancer J Clin. 70:7–30. 2020.PubMed/NCBI View Article : Google Scholar
2	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
3	Ayyub MI, Al-Radi AO, Khazeindar AM, Nagi AH and Maniyar IA: Clinicopathological trends in colorectal cancer in a tertiary care hospital. Saudi Med J. 23:160–163. 2002.PubMed/NCBI
4	Mosli MH and Al-Ahwal MS: Colorectal cancer in the kingdom of Saudi Arabia: Need for screening. Asian Pac J Cancer Prev. 13:3809–3813. 2012.PubMed/NCBI View Article : Google Scholar
5	Tiash S and Chowdhury EH: Growth factor receptors: Promising drug targets in cancer. J Cancer Metastasis Treat. 1:190–200. 2015.
6	Witsch E, Sela M and Yarden Y: Roles for growth factors in cancer progression. Physiology (Bethesda). 25:85–101. 2010.PubMed/NCBI View Article : Google Scholar
7	Kantola T, Klintrup K, Vayrynen JP, Vornanen J, Bloigu R, Karhu T, Herzig KH, Napankangas J, Mäkelä J, Karttunen TJ, et al: Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma. Br J Cancer. 107:1729–1736. 2012.PubMed/NCBI View Article : Google Scholar
8	Krzystek-Korpacka M, Diakowska D, Kapturkiewicz B, Bębenek M and Gamian A: Profiles of circulating inflammatory cytokines in colorectal cancer (CRC), high cancer risk conditions, and health are distinct. Possible implications for CRC screening and surveillance. Cancer Lett. 337:107–114. 2013.PubMed/NCBI View Article : Google Scholar
9	Tang Y, Liao C, Xu X, Song H, Shi S and Yang S: Th1/Th2 cytokine profiles in G+/G- bacteremia in pediatric hematology/oncology patients. Pediatr Blood Cancer. 58:50–54. 2012.PubMed/NCBI View Article : Google Scholar
10	Venere M, Lathia JD and Rich JN: Growth factor receptors define cancer hierarchies. Cancer Cell. 23:135–137. 2013.PubMed/NCBI View Article : Google Scholar
11	Cohen RB: Epidermal growth factor receptor as a therapeutic target in colorectal cancer. Clin Colorectal Cancer. 2:246–251. 2003.PubMed/NCBI View Article : Google Scholar
12	Pabla B, Bissonnette M and Konda VJ: Colon cancer and the epidermal growth factor receptor: Current treatment paradigms, the importance of diet, and the role of chemoprevention. World J Clin Oncol. 6:133–141. 2015.PubMed/NCBI View Article : Google Scholar
13	Cascinu S, Staccioli MP, Gasparini G, Giordani P, Catalano V, Ghiselli R, Rossi C, Baldelli AM, Graziano F, Saba V, et al: Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res. 6:2803–2807. 2000.PubMed/NCBI
14	Rapisarda A and Melillo G: Role of the VEGF/VEGFR axis in cancer biology and therapy. Adv Cancer Res. 114:237–267. 2012.PubMed/NCBI View Article : Google Scholar
15	Gohji K, Nomi M, Niitani Y, Kitazawa S, Fujii A, Katsuoka Y and Nakajima M: Independent prognostic value of serum hepatocyte growth factor in bladder cancer. J Clin Oncol. 18:2963–2971. 2000.PubMed/NCBI View Article : Google Scholar
16	Naughton M, Picus J, Zhu X, Catalona WJ, Vollmer RT and Humphrey PA: Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer. J Urol. 165:1325–1328. 2001.PubMed/NCBI
17	Toiyama Y, Miki C, Inoue Y, Okugawa Y, Tanaka K and Kusunoki M: Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients. Int J Cancer. 125:1657–1662. 2009.PubMed/NCBI View Article : Google Scholar
18	Hanzawa M, Shindoh M, Higashino F, Yasuda M, Inoue N, Hida K, Ono M, Kohgo T, Nakamura M, Notani K, et al: Hepatocyte growth factor upregulates E1AF that induces oral squamous cell carcinoma cell invasion by activating matrix metalloproteinase genes. Carcinogenesis. 21:1079–1085. 2000.PubMed/NCBI
19	Sobin LH and Compton CC: TNM seventh edition: What's new, what's changed: Communication from the International Union Against Cancer and the American Joint Committee on Cancer. Cancer. 116:5336–5339. 2010.PubMed/NCBI View Article : Google Scholar
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
21	Al Obeed OA, Alkhayal KA, Al Sheikh A, Zubaidi AM, Vaali-Mohammed MA, Boushey R, McKerrow JH and Abdulla MH: Increased expression of tumour necrosis factor-alpha is associated with advanced colorectal cancer stages. World J Gastroenterol. 20:18390–18396. 2014.PubMed/NCBI View Article : Google Scholar
22	Al Obeed OA, Alkhayal KA, Al Sheikh A, Zubaidi AM, Vaali-Mohammed MA, Boushey R, Mckerrow JH and Abdulla MH: Increased expression of tumor necrosis factor-α is associated with advanced colorectal cancer stages. World J Gastroenterol. 20:18390–18396. 2014.PubMed/NCBI View Article : Google Scholar
23	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011.PubMed/NCBI View Article : Google Scholar
24	De Divitiis C, Nasti G, Montano M, Fisichella R, Iaffaioli RV and Berretta M: Prognostic and predictive response factors in colorectal cancer patients: Between hope and reality. World J Gastroenterol. 20:15049–15059. 2014.PubMed/NCBI View Article : Google Scholar
25	Inanc M, Er O, Karaca H, Berk V, Ozkan M, Saraymen R and Elmali F: Prognostic value of tumour growth factor levels during chemotherapy in patients with metastatic colorectal cancer. Med Oncol. 29:3119–3124. 2012.PubMed/NCBI View Article : Google Scholar
26	Yoon SS, Kim SH, Gonen M, Heffernan NM, Detwiller KY, Jarnagin WR, D'Angelica M, Blumgart LH, Tanabe KK and Dematteo RP: Profile of plasma angiogenic factors before and after hepatectomy for colorectal cancer liver metastases. Ann Surg Oncol. 13:353–362. 2006.PubMed/NCBI View Article : Google Scholar
27	Bendardaf R, Buhmeida A, Hilska M, Laato M, Syrjänen S, Syrjänen K, Collan Y and Pyrhönen S: VEGF-1 expression in colorectal cancer is associated with disease localization, stage, and long-term disease-specific survival. Anticancer Res. 28:3865–3870. 2008.PubMed/NCBI
28	Liu J, Duan Y, Cheng X, Chen X, Xie W, Long H, Lin Z and Zhu B: IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun. 407:348–354. 2011.PubMed/NCBI View Article : Google Scholar
29	Martins SF, Garcia EA, Luz MA, Pardal F, Rodrigues M and Filho AL: Clinicopathological correlation and prognostic significance of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression in colorectal cancer. Cancer Genomics Proteomics. 10:55–67. 2013.PubMed/NCBI
30	Des Guetz G, Uzzan B, Nicolas P, Cucherat M, Morere JF, Benamouzig R, Breau JL and Perret GY: Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer. 94:1823–1832. 2006.PubMed/NCBI View Article : Google Scholar
31	Kwon KA, Kim SH, Oh SY, Lee S, Han JY, Kim KH, Goh RY, Choi HJ, Park KJ, Roh MS, et al: Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer. BMC Cancer. 10(203)2010.PubMed/NCBI View Article : Google Scholar
32	Eldesoky A, Shouma A, Mosaad Y and Elhawary A: Clinical relevance of serum vascular endothelial growth factor and interleukin-6 in patients with colorectal cancer. Saudi J Gastroenterol. 17:170–173. 2011.PubMed/NCBI View Article : Google Scholar
33	Lee JC, Chow NH, Wang ST and Huang SM: Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer. 36:748–753. 2000.PubMed/NCBI View Article : Google Scholar
34	Coşkun Ö, Öztopuz Ö and Özkan ÖF: Determination of IL-6, TNF-α and VEGF levels in the serums of patients with colorectal cancer. Cell Mol Biol (Noisy-le-grand). 63:97–101. 2017.PubMed/NCBI View Article : Google Scholar
35	George ML, Tutton MG, Janssen F, Arnaout A, Abulafi AM, Eccles SA and Swift RI: VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia. 3:420–427. 2001.PubMed/NCBI View Article : Google Scholar
36	Balcan E, Demirkiran F, Aydin Y, Sanioglu C, Bese T, Arvas M, Akçay T and Cift T: Serum levels of epidermal growth factor, transforming growth factor, and c-erbB2 in ovarian cancer. Int J Gynecol Cancer. 22:1138–1142. 2012.PubMed/NCBI View Article : Google Scholar
37	Spano JP, Lagorce C, Atlan D, Milano G, Domont J, Benamouzig R, Attar A, Benichou J, Martin A, Morere JF, et al: Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol. 16:102–108. 2005.PubMed/NCBI View Article : Google Scholar
38	Cheirsilpa A, Ruangvejvorachai P, Karalak A, Sangprakarn S, Pummai S and Sangrajrang S: Determination of epidermal growth factor receptor (EGFR) in patients with colorectal cancer. Cancer Ther. 5:137–142. 2007.
39	Arteaga CL: The epidermal growth factor receptor: From mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol. 19 (Suppl 18):S32–S40. 2001.PubMed/NCBI
40	Yarden Y: The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer. 37 (Suppl 4):S3–S8. 2001.PubMed/NCBI View Article : Google Scholar
41	Goldstein NS and Armin M: Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint committee on cancer stage IV colon adenocarcinoma: Implications for a standardized scoring system. Cancer. 92:1331–1346. 2001.PubMed/NCBI View Article : Google Scholar
42	Lemos-Gonzalez Y, Rodriguez-Berrocal FJ, Cordero OJ, Gómez C and Paez de la Cadena M: Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma. Br J Cancer. 96:1569–1578. 2007.PubMed/NCBI View Article : Google Scholar
43	Kermorgant S, Zicha D and Parker PJ: PKC controls HGF-dependent c-Met traffic, signalling and cell migration. EMBO J. 23:3721–3734. 2004.PubMed/NCBI View Article : Google Scholar
44	Li F and Zhu YT: HGF-activated colonic fibroblasts mediates carcinogenesis of colonic epithelial cancer cells via PKC-cMET-ERK1/2-COX-2 signaling. Cell Signal. 27:860–866. 2015.PubMed/NCBI View Article : Google Scholar
45	Yao JF, Li XJ, Yan LK, He S, Zheng JB, Wang XR, Zhou PH, Zhang L, Wei GB and Sun XJ: Role of HGF/c-Met in the treatment of colorectal cancer with liver metastasis. J Biochem Mol Toxicol. 33(e22316)2019.PubMed/NCBI View Article : Google Scholar
46	Easton DF and Eeles RA: Genome-wide association studies in cancer. Hum Mol Genet. 17:R109–R115. 2008.PubMed/NCBI View Article : Google Scholar
47	Vogel C and Marcotte EM: Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet. 13:227–232. 2012.PubMed/NCBI View Article : Google Scholar
48	Plaks V, Kong N and Werb Z: The cancer stem cell niche: How essential is the niche in regulating stemness of tumour cells? Cell Stem Cell. 16:225–238. 2015.PubMed/NCBI View Article : Google Scholar